Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T17091 | Thrombin Inhibitor 2 | Others | Others |
Thrombin Inhibitor 2 is a small molecule direct thrombin inhibitor. Thrombin Inhibitor 2 has antithrombotic activity. | |||
TP1046 |
SLIGRL-NH2
Protease-Activated Receptor-2 Activating Peptide |
Protease-activated Receptor | GPCR/G Protein |
SLIGRL-NH2 (Protease-Activated Receptor-2 Activating Peptide) 为一种蛋白酶激活受体-2 (PAR-2) 激动剂,具有诱导非组胺能性瘙痒的功能。 | |||
T1893 |
Parmodulin 2
ML 161 |
Protease-activated Receptor | GPCR/G Protein |
Parmodulin 2 (ML 161) 是一种蛋白酶激活受体 1(PAR1) 变构抑制剂,IC50为 0.26 μM。它是蛋白酶激活受体 1 (PAR1) 介导的血小板活化的抑制剂,可以抑制体外血小板聚集和体内血小板血栓形成。 | |||
T8917 |
PAR-2-IN-1
IUN76750,8-(叔丁基)-6-氯咪唑并[1,2-B]吡啶-2-羧酸甲酯 |
Protease-activated Receptor | GPCR/G Protein |
PAR-2-IN-1 (IUN76750) 是一种 PAR-2 信号通路抑制剂,具有抗炎和抗癌作用。 | |||
T7513 |
Protease-Activated Receptor-2, amide
蛋白酶活化的受体-2,酰胺,SLIGKV-NH2,H-丝氨酰亮氨酰异亮氨酰甘氨酰赖氨酰缬氨酰NH2 |
Protease-activated Receptor | GPCR/G Protein |
Protease-Activated Receptor-2, amide (SLIGKV-NH2) 是 PAR2 的激动剂,IC50为 10.4 M。 | |||
T10951 |
Dabigatran ethyl ester hydrochloride
N-[[2-[[[4-(氨基亚氨甲基)苯基]氨基]甲基]-1-甲基-1H-苯并咪唑-5-基]羰基]-N-(2-吡啶基)-BETA-丙氨酸乙酯盐酸盐 |
Others; Thrombin | Others; Proteases/Proteasome |
Dabigatran ethyl ester hydrochloride 是一种核糖基二氢烟酰胺脱氢酶抑制剂,IC50=0.8 μM,也是一种凝血酶的抑制剂。 | |||
T7573 |
TFLLR-NH2
TFLLR-NH2(2TFA) |
Protease-activated Receptor | GPCR/G Protein |
TFLLR-NH2 是选择性的一种PAR1激动剂,EC50值为1.9 μM。 | |||
T9892 |
JAMM protein inhibitor 2
Acetamide, 2-(2-ethylphenoxy)-N-[2-methyl-4-(1-pyrrolidinyl)phenyl]- |
Others | Others |
JAMM protein inhibitor 2 (Acetamide, 2-(2-ethylphenoxy)-N-[2-methyl-4-(1-pyrrolidinyl)phenyl]-) 是 JAMM 蛋白酶的抑制剂,可用于抗癌的研究。 对thrombin、Rpn11 和 MMP2 的 IC50 分别为 10 μM、46 μM 和 89 μM。 | |||
T77373 |
Concizumab
mAb 2021,NN 7415 |
Others | Others |
Concizumab 是一种 抗 TFPI 单克隆抗体 (IgG4 型),可选择性与 TFPI 的 Kunitz 型蛋白酶抑制剂 (KPI) 2 结构域结合,从而阻断该结构域与 FXa 活性位点的相互作用。注射 Concizumab 会使血液中凝血酶增加,可用于于预防和治疗血友病。 | |||
T2368L |
Edoxaban
Lixiana,依杜沙班 |
Factor Xa; Thrombin | Metabolism; Proteases/Proteasome |
Edoxaban (Lixiana) (DU-176) 是一种选择性的,口服有效的 factor Xa (FXa)抑制剂。Edoxaban 对游离 FXa 和凝血酶原的 Ki 分别为 0.561 nM 和 2.98 nM。Edoxaban 是一种抗凝剂,可用于预防中风。Edoxaban 还是一种凝血酶和凝血因子 IXaβ (FIXa) 的弱抑制剂,Ki 值分别为 6.00 μM 和 41.7 μM,对 FXa 的选择性超过 10000 倍。由于具有抗血栓形成的特性,Edoxaban 可用于预防血栓栓塞性疾病的研究。 | |||
T26657 |
AR-H067637
|
||
AR-H067637 is a rapid-binding, reversible and potent (inhibition constant K(i) = 2-4 nM), competitive inhibitor of thrombin, as well as of thrombin bound to fibrin (clot-bound thrombin) or to thrombomodulin. The total amount of free thrombin generated in | |||
T77221 | Benzenecarboximidamide, hydrochloride, hydrate (1:1:x) | ||
Benzenecarboximidamide, hydrochloride, hydrate (1:1:x) (Benzamidine hydrochloride hydrate) 是一种可逆的竞争性胰蛋白酶样丝氨酸蛋白酶 (trypsin-like serine proteases) 抑制剂,对 Tryptase、Trypsin、uPA、Factor Xa、Thrombin 和 tPA 的Ki 值分别为 20、21、97、110、320 和 750 μM。 | |||
T75242 |
Bivalirudin TFA
|
||
Bivalirudin TFA 是20个氨基多肽,可逆地抑制凝血酶。 | |||
T9670 |
Patamostat
|
||
Patamostat (E-3123)是一种有效的蛋白酶抑制剂,对胰蛋白酶、纤溶酶和凝血酶具有显著抑制效果,其IC50值分别为39 nM、950 nM和1.9 μM。Patamostat可能在急性胰腺炎的发病机制和发展中发挥抑制作用。 | |||
T36717 |
RWJ-56110 dihydrochloride
|
||
RWJ-56110 dihydrochloride is a potent, selective, peptide-mimetic inhibitor of PAR-1 activation and internalization (binding IC50=0.44 uM) and shows no effect on PAR-2, PAR-3, or PAR-4. RWJ-56110 dihydrochloride inhibits the aggregation of human platelets induced by both SFLLRN-NH2 (IC50=0.16 μM) and thrombin (IC50=0.34 μM), quite selective relative to U46619 . RWJ-56110 dihydrochloride blocks angiogenesis and blocks the formation of new vessels in vivo. RWJ-56110 dihydrochloride induces cell ap... |